ACXP

Acurx Pharmaceuticals Inc

• NASDAQ·4d ago

  Acurx Pharmaceuticals, Inc. Amends Bylaws to Reduce Stockholder Quorum to 33⅓%

• TipRanks·10/29 21:49

  Acurx Pharmaceuticals Lowers Quorum for Shareholder Meetings

• Dow Jones·10/26 12:01

  Press Release: Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update

• PR Newswire·10/21 12:01

  Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect

• TipRanks·10/16 21:00

  Acurx Pharmaceuticals Shareholders Approve Governance and Auditing Changes

• TipRanks·09/30 08:50

  Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Tectonic Therapeutic (TECX)

• TipRanks·09/29 15:55

  Advancing C. Difficile Program Supports Unchanged $31 Price Target and Buy Rating

• Dow Jones·09/29 15:53

  Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co.

• TipRanks·09/29 12:21

  Acurx enrolls first patient in clinical trial of Ibezapolstat in rCDI

• TipRanks·09/08 20:30

  Acurx registers to sell 1.5M shares of common stock for holders

• TipRanks·08/19 19:40

  Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

• NASDAQ·08/18 05:29

  Acurx Gets FDA Conditional Acceptance, U.S. Patents Trademark Allowance For Ibezapolstat Brand Name

• TipRanks·08/17 12:05

  Acurx announces FDA conditional approval of CIFBEZY as brand name for ibezapolst

• TipRanks·08/17 09:42

  Acurx receives patents for DNA Polymerase IIIC inhibitors in Mexico and Japan

• TipRanks·08/15 00:24

  Acurx Pharmaceuticals Earnings Call Highlights Funding Risk